Driving GDNF expression: The green and the red traffic lights

Progress in Neurobiology

Volumn 86, Issue 3, 2008, Pages 186-215

  Saavedra, Ana ^a   Baltazar, Graça ^b   Duarte, Emília P ^c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Activity dependence; Development; Endogenous expression; GDNF; GDNF gene; Inflammation; Injury; Neuron glia cross talk; Neuroprotection; Nigrostriatal system; Parkinson's disease; Signalling pathways

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLOZAPINE; COLECALCIFEROL; CYCLOSPORIN A; DIAZEPAM; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; ESTROGEN; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; IMMUNOPHILIN; KETANSERIN; LEVODOPA; MELATONIN; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NOOTROPIC AGENT; NORADRENALIN; PAROXETINE; SELEGILINE; UNINDEXED DRUG; VALPROIC ACID;

BRAIN INJURY; CALORIC RESTRICTION; DOPAMINERGIC TRANSMISSION; EXERCISE; GLIA CELL; KIDNEY DEVELOPMENT; NERVOUS SYSTEM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MODELS, BIOLOGICAL; NERVOUS SYSTEM; SIGNAL TRANSDUCTION;

EID: 55049090172     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2008.09.006     Document Type: Review

References (453)

1. Abel T., and Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8 (2008) 57-64
2. Adalsteinsson H., and Bruice T.C. Generation and evaluation of putative neuroregenerative drugs. Part 2. Screening virtual libraries of novel polyketides which possess the binding domain of rapamycin. Bioorg. Med. Chem. 8 (2000) 625-635
3. Albeck D.S., Hoffer B.J., Quissell D., Sanders L.A., Zerbe G., and Granholm A.C. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 8 (1997) 2293-2298
4. Alfano I., Vora P., Mummery R.S., Mulloy B., and Rider C.C. The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochem. J. 404 (2007) 131-140
5. Anastasia A., de Erausquin G.A., Wojnacki J., and Masco D.H. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease. J. Neurochem. 103 (2007) 1542-1552
6. Angelucci F., Aloe L., Jimenez-Vasquez P., and Mathe A.A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int. J. Neuropsychopharmacol. 6 (2003) 225-231
7. Anton-Tay F., Ramirez G., Martinez I., and Benitez-King G. In vitro stimulation of protein kinase C by melatonin. Neurochem. Res. 23 (1998) 601-606
8. Appel E., Kolman O., Kazimirsky G., Blumberg P.M., and Brodie C. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. Neuroreport 8 (1997) 3309-3312
9. Araki T., Kumagai T., Tanaka K., Matsubara M., Kato H., Itoyama Y., and Imai Y. Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res. 918 (2001) 176-181
10. Arenas E., Trupp M., Akerud P., and Ibanez C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15 (1995) 1465-1473
11. Armistead D.M., Badia M.C., Deininger D.D., Duffy J.P., Saunders J.O., Tung R.D., Thomson J.A., DeCenzo M.T., Futer O., Livingston D.J., Murcko M.A., Yamashita M.M., and Navia M.A. Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr. D: Biol. Crystallogr. 51 (1995) 522-528
12. Armstrong K.J., and Niles L.P. Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 13 (2002) 473-475
13. Backman C.M., Shan L., Zhang Y.J., Hoffer B.J., Leonard S., Troncoso J.C., Vonsatel P., and Tomac A.C. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol. Cell. Endocrinol. 252 (2006) 160-166
14. Baecker P.A., Lee W.H., Verity A.N., Eglen R.M., and Johnson R.M. Characterization of a promoter for the human glial cell line-derived neurotrophic factor gene. Brain Res. Mol. Brain Res. 69 (1999) 209-222
15. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., Leitner M.L., Araki T., Johnson Jr. E.M., and Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 (1998) 1291-1302
16. Bar-Am O., Weinreb O., Amit T., and Youdim M.B. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Faseb J. 19 (2005) 1899-1901
17. Barneoud P., Mazadier M., Miquet J.M., Parmentier S., Dubedat P., Doble A., and Boireau A. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74 (1996) 971-983
18. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 61 (2003) S12-S16
19. Barroso-Chinea P., Cruz-Muros I., Aymerich M.S., Rodriguez-Diaz M., Afonso-Oramas D., Lanciego J.L., and Gonzalez-Hernandez T. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur. J. Neurosci. 21 (2005) 1815-1827
20. Basson M.A., Akbulut S., Watson-Johnson J., Simon R., Carroll T.J., Shakya R., Gross I., Martin G.R., Lufkin T., McMahon A.P., Wilson P.D., Costantini F.D., Mason I.J., and Licht J.D. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev. Cell 8 (2005) 229-239
21. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., and Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19 (1999) 1708-1716
22. Bauer M., Suppmann S., Meyer M., Hesslinger C., Gasser T., Widmer H.R., and Ueffing M. Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones. J. Neurochem. 82 (2002) 1300-1310
23. Benazzouz A., Boraud T., Dubedat P., Boireau A., Stutzmann J.M., and Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol. 284 (1995) 299-307
24. Benn S.C., and Woolf C.J. Adult neuron survival strategies-slamming on the brakes. Nat. Rev. Neurosci. 5 (2004) 686-700
25. Bespalov M.M., and Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci. 28 (2007) 68-74
26. Bezard E., Dovero S., Belin D., Duconger S., Jackson-Lewis V., Przedborski S., Piazza P.V., Gross C.E., and Jaber M. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J. Neurosci. 23 (2003) 10999-11007
27. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 (2003) 215-221
28. Bezard E., Stutzmann J.M., Imbert C., Boraud T., Boireau A., and Gross C.E. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur. J. Pharmacol. 356 (1998) 101-104
29. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., and Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 8818-8823
30. Bizon J.L., Lauterborn J.C., and Gall C.M. Subpopulations of striatal interneurons can be distinguished on the basis of neurotrophic factor expression. J. Comp. Neurol. 408 (1999) 283-298
31. Bjerken S.A., Boger H.A., Nelson M., Hoffer B.J., Granholm A.C., and Stromberg I. Effects of glial cell line-derived neurotrophic factor deletion on ventral mesencephalic organotypic tissue cultures. Brain Res. 1133 (2007) 10-19
32. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
33. Blum M., and Weickert C.S. GDNF mRNA expression in normal postnatal development, aging, and in Weaver mutant mice. Neurobiol. Aging 16 (1995) 925-929
34. Boado R.J., Zhang Y., Zhang Y., Wang Y., and Pardridge W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng. 100 (2007) 387-396
35. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., and Granholm A.C. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol. 202 (2006) 336-347
36. Bonde C., Sarup A., Schousboe A., Gegelashvili G., Noraberg J., and Zimmer J. GDNF pre-treatment aggravates neuronal cell loss in oxygen-glucose deprived hippocampal slice cultures: a possible effect of glutamate transporter up-regulation. Neurochem. Int. 43 (2003) 381-388
37. Bouchard M. Transcriptional control of kidney development. Differentiation 72 (2004) 295-306
38. Bourque M.J., and Trudeau L.E. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. Eur. J. Neurosci. 12 (2000) 3172-3180
39. Bozzi Y., and Borrelli E. Absence of the dopamine D2 receptor leads to a decreased expression of GDNF and NT-4 mRNAs in restricted brain areas. Eur. J. Neurosci. 11 (1999) 1275-1284
40. Bredy T.W., and Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn. Mem. 15 (2008) 39-45
41. Bredy T.W., Wu H., Crego C., Zellhoefer J., Sun Y.E., and Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 14 (2007) 268-276
42. Bresjanac M., and Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo. Exp. Neurol. 164 (2000) 53-59
43. Brodbeck S., and Englert C. Genetic determination of nephrogenesis: the Pax/Eya/Six gene network. Pediatr. Nephrol. 19 (2004) 249-255
44. Brodbeck S., Besenbeck B., and Englert C. The transcription factor Six2 activates expression of the Gdnf gene as well as its own promoter. Mech. Dev. 121 (2004) 1211-1222
45. Brophy P.D., Ostrom L., Lang K.M., and Dressler G.R. Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene. Development 128 (2001) 4747-4756
46. Buj-Bello A., Buchman V.L., Horton A., Rosenthal A., and Davies A.M. GDNF is an age-specific survival factor for sensory and autonomic neurons. Neuron 15 (1995) 821-828
47. Burke R.E. Postnatal developmental programmed cell death in dopamine neurons. Ann. NY Acad. Sci. 991 (2003) 69-79
48. Burke R.E., Antonelli M., and Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71 (1998) 517-525
49. Cabrera J.R., Sanchez-Pulido L., Rojas A.M., Valencia A., Manes S., Naranjo J.R., and Mellstrom B. Gas1 is related to the glial cell-derived neurotrophic factor family receptors alpha and regulates Ret signaling. J. Biol. Chem. 281 (2006) 14330-14339
50. Cadet P., Zhu W., Mantione K., Rymer M., Dardik I., Reisman S., Hagberg S., and Stefano G.B. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. Int. J. Mol. Med. 12 (2003) 485-492
51. Callier S., Morissette M., Grandbois M., Pelaprat D., and Di P.T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 (2001) 131-138
52. Canossa M., Griesbeck O., Berninger B., Campana G., Kolbeck R., and Thoenen H. Neurotrophin release by neurotrophins: implications for activity-dependent neuronal plasticity. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13279-13286
53. Cao J.P., Yu J.K., Li C., Sun Y., Yuan H.H., Wang H.J., and Gao D.S. Integrin beta1 is involved in the signaling of glial cell line-derived neurotrophic factor. J. Comp. Neurol. 509 (2008) 203-210
54. Carro E., and Torres-Aleman I. Serum insulin-like growth factor I in brain function. Keio J. Med. 55 (2006) 59-63
55. Carrillo M.C., Kanai S., Nokubo M., and Kitani K. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48 (1991) 517-521
56. Castro L.M., Gallant M., and Niles L.P. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J. Neurochem. 95 (2005) 1227-1236
57. Caumont A.S., Octave J.N., and Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci. Lett. 394 (2006) 196-201
58. Caumont A.S., Octave J.N., and Hermans E. Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells. J. Neurochem. 97 (2006) 128-139
59. Cen X., Nitta A., Ohya S., Zhao Y., Ozawa N., Mouri A., Ibi D., Wang L., Suzuki M., Saito K., Ito Y., Kawagoe T., Noda Y., Ito Y., Furukawa S., and Nabeshima T. An analog of a dipeptide-like structure of FK506 increases glial cell line-derived neurotrophic factor expression through cAMP response element-binding protein activated by heat shock protein 90/Akt signaling pathway. J. Neurosci. 26 (2006) 3335-3344
60. Chadi G., Moller A., Rosen L., Janson A.M., Agnati L.A., Goldstein M., Ogren S.O., Pettersson R.F., and Fuxe K. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res. 97 (1993) 145-158
61. Chao C.C., and Lee E.H. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. Neuropharmacology 38 (1999) 913-916
62. Chauhan N.B., Siegel G.J., and Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21 (2001) 277-288
63. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., and Ascherio A. Physical activity and the risk of Parkinson disease. Neurology 64 (2005) 664-669
64. Chen K.B., Lin A.M., and Chiu T.H. Oxidative injury to the locus coeruleus of rat brain: neuroprotection by melatonin. J. Pineal Res. 35 (2003) 109-117
65. Chen L.W., Wang Y.Q., Wei L.C., Shi M., and Chan Y.S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets 6 (2007) 273-281
66. Chen L.W., Yung K.L., and Chan Y.S. Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. Curr. Drug Targets 6 (2005) 821-833
67. Chen L.W., Zhang J.P., Kwok-Yan S.D., and Chan Y.S. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice. J. Comp. Neurol. 497 (2006) 898-909
68. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006) 1116-1125
69. Chen Y., Ai Y., Slevin J.R., Maley B.E., and Gash D.M. Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp. Neurol. 196 (2005) 87-95
70. Cheng H., Fu Y.S., and Guo J.W. Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus 14 (2004) 77-86
71. Cheng H., Wu J.P., and Tzeng S.F. Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury. J. Neurosci. Res. 69 (2002) 397-405
72. Choi-Lundberg D.L., and Bohn M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res. Dev. Brain Res. 85 (1995) 80-88
73. Chung V., Liu L., Bian Z., Zhao Z., Leuk F.W., Kum W.F., Gao J., and Li M. Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review. Mov. Disord. 21 (2006) 1709-1715
74. Ciccarelli R., Di Iorio P., Bruno V., Battaglia G., D'Alimonte I., D'Onofrio M., Nicoletti F., and Caciagli F. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27 (1999) 275-281
75. Clarke C.E., and Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 360 (2002) 1767-1769
76. Cohen A.D., Tillerson J.L., Smith A.D., Schallert T., and Zigmond M.J. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J. Neurochem. 85 (2003) 299-305
77. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., and Yahr M.D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106 (1984) 209-210
78. Collier T.J., Dung L.Z., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp. Neurol. 191 Suppl. 1 (2005) S60-S67
79. Costantini F., and Shakya R. GDNF/Ret signaling and the development of the kidney. Bioessays 28 (2006) 117-127
80. Costantini L.C., and Isacson O. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. Exp. Neurol. 164 (2000) 60-70
81. Costantini L.C., Chaturvedi P., Armistead D.M., McCaffrey P.G., Deacon T.W., and Isacson O. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol. Dis. 5 (1998) 97-106
82. Costantini L.C., Cole D., Chaturvedi P., and Isacson O. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur. J. Neurosci. 13 (2001) 1085-1092
83. Cotman C.W., and Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25 (2002) 295-301
84. Dabbeni-Sala F., Di S.S., Franceschini D., Skaper S.D., and Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. Faseb J. 15 (2001) 164-170
85. Darlington C.L. Astrocytes as targets for neuroprotective drugs. Curr. Opin. Invest. Drugs 6 (2005) 700-703
86. D'Astous M., Morissette M., and Di P.T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47 (2004) 1180-1188
87. Delyfer M.N., Simonutti M., Neveux N., Leveillard T., and Sahel J.A. Does GDNF exert its neuroprotective effects on photoreceptors in the rd1 retina through the glial glutamate transporter GLAST?. Mol. Vis. 11 (2005) 677-687
88. Diehl J.A., Tong W., Sun G., and Hannink M. Tumor necrosis factor-alpha-dependent activation of a RelA homodimer in astrocytes. Increased phosphorylation of RelA and MAD-3 precede activation of RelA. J. Biol. Chem. 270 (1995) 2703-2707
89. Dietz G.P., Valbuena P.C., Dietz B., Meuer K., Mueller P., Weishaupt J.H., and Bahr M. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 1082 (2006) 61-66
90. Ding Y.M., Jaumotte J.D., Signore A.P., and Zigmond M.J. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J. Neurochem. 89 (2004) 776-787
91. Dluzen D.E., McDermott J.L., and Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 66 (1996) 658-666
92. Dong A., Shen J., Krause M., Hackett S.F., and Campochiaro P.A. Increased expression of glial cell line-derived neurotrophic factor protects against oxidative damage-induced retinal degeneration. J. Neurochem. 103 (2007) 1041-1052
93. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 22 (2005) 2422-2430
94. Duan W., and Mattson M.P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57 (1999) 195-206
95. Dubocovich M.L., Rivera-Bermudez M.A., Gerdin M.J., and Masana M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. 8 (2003) d1093-d1108
96. Egger T., Schuligoi R., Wintersperger A., Amann R., Malle E., and Sattler W. Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia. Biochem. J. 370 (2003) 459-467
97. Egnaczyk G.F., Pomonis J.D., Schmidt J.A., Rogers S.D., Peters C., Ghilardi J.R., Mantyh P.W., and Maggio J.E. Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics 3 (2003) 689-698
98. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., and Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23 (2003) 7311-7316
99. Engele J., and Lehner M. Regulation of glial-derived dopaminergic growth factors by glucocorticoids and protein kinase C. Exp. Neurol. 133 (1995) 18-24
100. Enomoto H. Regulation of neural development by glial cell line-derived neurotrophic factor family ligands. Anat. Sci. Int. 80 (2005) 42-52
101. Esquela A.F., and Lee S.J. Regulation of metanephric kidney development by growth/differentiation factor 11. Dev. Biol. 257 (2003) 356-370
102. 3 and brain development. Neuroscience 118 (2003) 641-653
103. Faherty C.J., Raviie S.K., Herasimtschuk A., and Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental parkinsonism. Brain Res. Mol. Brain Res. 134 (2005) 170-179
104. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252 Suppl. 4 (2005) IV37-IV42
105. Feng L., Wang C.Y., Jiang H., Oho C., Dugich-Djordjevic M., Mei L., and Lu B. Differential signaling of glial cell line-derived neurothrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons. Neuroscience 93 (1999) 265-273
106. 3 deficiency alters the adult rat brain. Brain Res. Bull. 65 (2005) 141-148
107. Finch C.E. The neurotoxicology of hard foraging and fat-melts. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17887-17888
108. Fisher B.E., Petzinger G.M., Nixon K., Hogg E., Bremmer S., Meshul C.K., and Jakowec M.W. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J. Neurosci. Res. 77 (2004) 378-390
109. Foley A.G., Gallagher H.C., Murphy K.J., and Regan C.M. Pentyl-4-yn-valproic acid reverses age-associated memory impairment in the Wistar rat. Neurobiol. Aging 25 (2004) 539-546
110. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., and Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 158 (2001) 100-106
111. Gage H., and Storey L. Rehabilitation for Parkinson's disease: a systematic review of available evidence. Clin. Rehabil. 18 (2004) 463-482
112. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., and Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann. Neurol. 58 (2005) 224-233
113. Gerlai R., McNamara A., Choi-Lundberg D.L., Armanini M., Ross J., Powell-Braxton L., and Phillips H.S. Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur. J. Neurosci. 14 (2001) 1153-1163
114. Ghribi O., Herman M.M., Forbes M.S., DeWitt D.A., and Savory J. GDNF protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. Neurobiol. Dis. 8 (2001) 764-773
115. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
116. Glatt S.L., Hubble J.P., Lyons K., Paolo A., Troster A.I., Hassanein R.E., and Koller W.C. Risk factors for dementia in Parkinson's disease: effect of education. Neuroepidemiology 15 (1996) 20-25
117. Gloire G., Legrand-Poels S., and Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72 (2006) 1493-1505
118. Gomez-Pinilla F., Dao L., and So V. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res. 764 (1997) 1-8
119. Granholm A.C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., and Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci. 20 (2000) 3182-3190
120. Grieshammer U., Le M., Plump A.S., Wang F., Tessier-Lavigne M., and Martin G.R. Slit2-mediated Robo2 signaling restricts kidney induction to a single site. Dev. Cell 6 (2004) 709-717
121. Grimm L., Holinski-Feder E., Teodoridis J., Scheffer B., Schindelhauer D., Meitinger T., and Ueffing M. Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3′-UTR and alternative splice products. Hum. Mol. Genet. 7 (1998) 1873-1886
122. Grunblatt E., Mandel S., Maor G., and Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78 (2001) 1-12
123. Grunblatt E., Mandel S., Maor G., and Youdim M.B. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77 (2001) 146-156
124. Guo H., Tang Z., Yu Y., Xu L., Jin G., and Zhou J. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur. J. Neurosci. 16 (2002) 1861-1870
125. Guo X., Dawson V.L., and Dawson T.M. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur. J. Neurosci. 13 (2001) 1683-1693
126. Hallett P.J., and Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 102 (2004) 155-174
127. Hashimoto K., Shimizu E., and Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 45 (2004) 104-114
128. Hashimoto M., Kanda M., Ikeno K., Hayashi Y., Nakamura T., Ogawa Y., Fukumitsu H., Nomoto H., and Furukawa S. Oral administration of royal jelly facilitates mRNA expression of glial cell line-derived neurotrophic factor and neurofilament H in the hippocampus of the adult mouse brain. Biosci. Biotechnol. Biochem. 69 (2005) 800-805
129. Hashimoto M., Nitta A., Fukumitsu H., Nomoto H., Shen L., and Furukawa S. Involvement of glial cell line-derived neurotrophic factor in activation processes of rodent macrophages. J. Neurosci. Res. 79 (2005) 476-487
130. Hashimoto M., Nitta A., Fukumitsu H., Nomoto H., Shen L., and Furukawa S. Inflammation-induced GDNF improves locomotor function after spinal cord injury. Neuroreport 16 (2005) 99-102
131. Hayashi H., Ichihara M., Iwashita T., Murakami H., Shimono Y., Kawai K., Kurokawa K., Murakumo Y., Imai T., Funahashi H., Nakao A., and Takahashi M. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19 (2000) 4469-4475
132. He D.Y., and Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. Faseb J. 20 (2006) 2420-2422
133. He D.Y., McGough N.N., Ravindranathan A., Jeanblanc J., Logrip M.L., Phamluong K., Janak P.H., and Ron D. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J. Neurosci. 25 (2005) 619-628
134. Hearn C.J., Murphy M., and Newgreen D. GDNF and ET-3 differentially modulate the numbers of avian enteric neural crest cells and enteric neurons in vitro. Dev. Biol. 197 (1998) 93-105
135. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
136. Henderson, C.E., Phillips, H.S., Pollock, R.A., Davies, A.M., Lemeulle, C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R.A., Simpson, L.C. [corrected to Simmons, L.], et al., 1994. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266, 1062-1064.
137. Hermann D.M., Kilic E., Kugler S., Isenmann S., and Bahr M. Adenovirus-mediated glial cell line-derived neurotrophic factor (GDNF) expression protects against subsequent cortical cold injury in rats. Neurobiol. Dis. 8 (2001) 964-973
138. Heuckeroth R.O., Lampe P.A., Johnson E.M., and Milbrandt J. Neurturin and GDNF promote proliferation and survival of enteric neuron and glial progenitors in vitro. Dev. Biol. 200 (1998) 116-129
139. Hida H., Jung C.G., Wu C.Z., Kim H.J., Kodama Y., Masuda T., and Nishino H. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur. J. Neurosci. 17 (2003) 2127-2134
140. Hisaoka K., Maeda N., Tsuchioka M., and Takebayashi M. Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: a possible contribution to GDNF production. Brain Res. 1196 (2008) 53-58
141. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., Ohta M., and Yamawaki S. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J. Neurochem. 79 (2001) 25-34
142. Hisaoka K., Nishida A., Takebayashi M., Koda T., Yamawaki S., and Nakata Y. Serotonin increases glial cell line-derived neurotrophic factor release in rat C6 glioblastoma cells. Brain Res. 1002 (2004) 167-170
143. Hisaoka K., Takebayashi M., Tsuchioka M., Maeda N., Nakata Y., and Yamawaki S. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J. Pharmacol. Exp. Ther. 321 (2007) 148-157
144. Ho A., and Blum M. Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice. Exp. Neurol. 148 (1997) 348-359
145. Ho A., Gore A.C., Weickert C.S., and Blum M. Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. Neuroreport 6 (1995) 1454-1458
146. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., and Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 166 (2000) 127-135
147. Hsuan S.L., Klintworth H.M., and Xia Z. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci. 26 (2006) 4481-4491
148. Hughes P.E., Alexi T., Walton M., Williams C.E., Dragunow M., Clark R.G., and Gluckman P.D. Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system. Prog. Neurobiol. 57 (1999) 421-450
149. Humpel C., Hoffer B., Stromberg I., Bektesh S., Collins F., and Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 59 (1994) 791-795
150. Hunot S., Bernard V., Faucheux B., Boissiere F., Leguern E., Brana C., Gautris P.P., Guerin J., Bloch B., Agid Y., and Hirsch E.C. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post-mortem in situ hybridization study with special reference to Parkinson's disease. J. Neural Transm. 103 (1996) 1043-1052
151. Hunt A.E., Al-Ghoul W.M., Gillette M.U., and Dubocovich M.L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol.: Cell Physiol. 280 (2001) C110-C118
152. Igarashi Y., Utsumi H., Chiba H., Yamada-Sasamori Y., Tobioka H., Kamimura Y., Furuuchi K., Kokai Y., Nakagawa T., Mori M., and Sawada N. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem. Biophys. Res. Commun. 261 (1999) 108-112
153. Iida M., Miyazaki I., Tanaka K., Kabuto H., Iwata-Ichikawa E., and Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838 (1999) 51-59
154. Ikeda T., Koo H., Xia Y.X., Ikenoue T., and Choi B.H. Bimodal upregulation of glial cell line-derived neurotrophic factor (GDNF) in the neonatal rat brain following ischemic/hypoxic injury. Int. J. Dev. Neurosci. 20 (2002) 555-562
155. Inoue T., Tsui J., Wong N., Wong S.Y., Suzuki F., and Kwok Y.N. Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res. 826 (1999) 306-308
156. Irie F., and Hirabayashi Y. Ceramide prevents motoneuronal cell death through inhibition of oxidative signal. Neurosci. Res. 35 (1999) 135-144
157. Ivanova T., Karolczak M., and Beyer C. Estradiol stimulates GDNF expression in developing hypothalamic neurons. Endocrinology 143 (2002) 3175-3178
158. Iwase T., Jung C.G., Bae H., Zhang M., and Soliven B. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J. Neurochem. 94 (2005) 1488-1499
159. Jackson M., Llado J., and Rothstein J.D. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin. Invest. Drugs 11 (2002) 1343-1364
160. Jadavji N.M., Kolb B., and Metz G.A. Enriched environment improves motor function in intact and unilateral dopamine-depleted rats. Neuroscience 140 (2006) 1127-1138
161. Jaumotte J.D., and Zigmond M.J. Dopaminergic innervation of forebrain by ventral mesencephalon in organotypic slice co-cultures: effects of GDNF. Brain Res. Mol. Brain Res. 134 (2005) 139-146
162. Jin G., Omori N., Li F., Nagano I., Manabe Y., Shoji M., and Abe K. Protection against ischemic brain damage by GDNF affecting cell survival and death signals. Neurol. Res. 25 (2003) 249-253
163. Jokinen P., Brück A., Aalto S., Forsback S., Parkkola R., and Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism. Rel. Disord. (2008) doi:10.1016/j.parkreldis.2008.03.005
164. Joo W.S., Jin B.K., Park C.W., Maeng S.H., and Kim Y.S. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 9 (1998) 4123-4126
165. Jourdain S., Morissette M., Morin N., and Di P.T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J. Neuroendocrinol. 17 (2005) 509-517
166. Kalechman Y., Gafter U., Da J.P., Albeck M., Arcon-Segovia D., and Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J. Immunol. 159 (1997) 2658-2667
167. Kalechman Y., Sredni B., Weinstein T., Freidkin I., Tobar A., Albeck M., and Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. J. Am. Soc. Nephrol. 14 (2003) 620-630
168. Kalechman Y., Zuloff A., Albeck M., Strassmann G., and Sredni B. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0′)tellurate. Blood 85 (1995) 1555-1561
169. Kastin A.J., Akerstrom V., and Pan W. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci. Lett. 340 (2003) 239-241
170. Kholodilov N., Yarygina O., Oo T.F., Zhang H., Sulzer D., Dauer W., and Burke R.E. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. J. Neurosci. 24 (2004) 3136-3146
171. Kilic E., Kilic U., and Hermann D.M. TAT-GDNF in neurodegeneration and ischemic stroke. CNS Drug Rev. 11 (2005) 369-378
172. Kinameri E., and Matsuoka I. Autocrine action of BMP2 regulates expression of GDNF-mRNA in sciatic Schwann cells. Brain Res. Mol. Brain Res. 117 (2003) 221-227
173. Kinor N., Geffen R., Golomb E., Zinman T., and Yadid G. Dopamine increases glial cell line-derived neurotrophic factor in human fetal astrocytes. Glia 33 (2001) 143-150
174. Kipp M., Karakaya S., Pawlak J., Raujo-Wright G., Arnold S., and Beyer C. Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. Front. Neuroendocrinol. 27 (2006) 376-390
175. Kirik D., Georgievska B., and Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7 (2004) 105-110
176. Kitamura T., Mishina M., and Sugiyama H. Dietary restriction increases hippocampal neurogenesis by molecular mechanisms independent of NMDA receptors. Neurosci. Lett. 393 (2006) 94-96
177. Klettner A., Baumgrass R., Zhang Y., Fischer G., Burger E., Herdegen T., and Mielke K. The neuroprotective actions of FK506 binding protein ligands: neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin. Brain Res. Mol. Brain Res. 97 (2001) 21-31
178. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82 (1998) 57-66
179. Knoll J., Yoneda F., Knoll B., Ohde H., and Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br. J. Pharmacol. 128 (1999) 1723-1732
180. Kobayashi H., Kawakami K., Asashima M., and Nishinakamra R. Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects. Mech. Dev. 124 (2007) 290-303
181. Kobori N., Waymire J.C., Haycock J.W., Clifton G.L., and Dash P.K. Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor. J. Biol. Chem. 279 (2004) 2182-2191
182. Koeberle P.D., and Bahr M. The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS. Cell Death Differ. 15 (2008) 471-483
183. Koh J.Y., Kim D.K., Hwang J.Y., Kim Y.H., and Seo J.H. Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J. Neurochem. 72 (1999) 716-723
184. Kornhuber J., Weller M., Schoppmeyer K., and Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. Suppl. 43 (1994) 91-104
185. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson Jr. E.M., and Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
186. Koutsilieri E., O'Callaghan J.F., Chen T.S., Riederer P., and Rausch W.D. Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons. Eur. J. Pharmacol. 269 (1994) R3-R4
187. Koyama Y., Egawa H., Osakada M., Baba A., and Matsuda T. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes. Biochem. Pharmacol. 68 (2004) 275-282
188. Koyama Y., Tsujikawa K., Matsuda T., and Baba A. Endothelin-1 stimulates glial cell line-derived neurotrophic factor expression in cultured rat astrocytes. Biochem. Biophys. Res. Commun. 303 (2003) 1101-1105
189. Koyama Y., Tsujikawa K., Matsuda T., and Baba A. Intracerebroventricular administration of an endothelin ETB receptor agonist increases expressions of GDNF and BDNF in rat brain. Eur. J. Neurosci. 18 (2003) 887-894
190. Kramer E.R., Aron L., Ramakers G.M., Seitz S., Zhuang X., Beyer K., Smidt M.P., and Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 5 (2007) e39
191. Kume T., Deng K., and Hogan B.L. Murine forkhead/winged helix genes Foxc1 (Mf1) and Foxc2 (Mfh1) are required for the early organogenesis of the kidney and urinary tract. Development 127 (2000) 1387-1395
192. Kuno R., Yoshida Y., Nitta A., Nabeshima T., Wang J., Sonobe Y., Kawanokuchi J., Takeuchi H., Mizuno T., and Suzumura A. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res. 1116 (2006) 12-18
193. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J. Antiaging Med. 6 (2003) 21-28
194. Lannes B., and Micheletti G. Sensitization of the striatal dopaminergic system induced by chronic administration of a glutamate antagonist in the rat. Neurosci. Biobehav. Rev. 21 (1997) 417-424
195. Larsen K.E., Benn S.C., Ay I., Chian R.J., Celia S.A., Remington M.P., Bejarano M., Liu M., Ross J., Carmillo P., Sah D., Phillips K.A., Sulzer D., Pepinsky R.B., Fishman P.S., Brown Jr. R.H., and Francis J.W. A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. Brain Res. 1120 (2006) 1-12
196. Larsen J.P., and Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov. Disord. 12 (1997) 175-182
197. Ledda F., Bieraugel O., Fard S.S., Vilar M., and Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J. Neurosci. 28 (2008) 39-49
198. Ledda F., Paratcha G., Sandoval-Guzman T., and Ibanez C.F. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat. Neurosci. 10 (2007) 293-300
199. Lee J., Duan W., and Mattson M.P. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 82 (2002) 1367-1375
200. Lee J., Duan W., Long J.M., Ingram D.K., and Mattson M.P. Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J. Mol. Neurosci. 15 (2000) 99-108
201. Lee S.H., Chun W., Kong P.J., Han J.A., Cho B.P., Kwon O.Y., Lee H.J., and Kim S.S. Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus. J. Pineal Res. 40 (2006) 79-85
202. Lehman D.A., Toole T., Lofald D., and Hirsch M.A. Training with verbal instructional cues results in near-term improvement of gait in people with Parkinson disease. J. Neurol. Phys. Ther. 29 (2005) 2-8
203. Lenhard T., Schober A., Suter-Crazzolara C., and Unsicker K. Fibroblast growth factor-2 requires glial-cell-line-derived neurotrophic factor for exerting its neuroprotective actions on glutamate-lesioned hippocampal neurons. Mol. Cell Neurosci. 20 (2002) 181-197
204. Leuner B., Gould E., and Shors T.J. Is there a link between adult neurogenesis and learning?. Hippocampus 16 (2006) 216-224
205. Levy Y.S., Gilgun-Sherki Y., Melamed E., and Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 19 (2005) 97-127
206. Li A., Guo H., Luo X., Sheng J., Yang S., Yin Y., Zhou J., and Zhou J. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. Faseb J. 20 (2006) 1263-1265
207. Li L., Su Y., Zhao C., Zhao H., Liu G., Wang J., and Xu Q. The role of Ret receptor tyrosine kinase in dopaminergic neuron development. Neuroscience 142 (2006) 391-400
208. Li S., Wang L., Berman M.A., Zhang Y., and Dorf M.E. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol. Cell 24 (2006) 497-509
209. Li X., Oghi K.A., Zhang J., Krones A., Bush K.T., Glass C.K., Nigam S.K., Aggarwal A.K., Maas R., Rose D.W., and Rosenfeld M.G. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426 (2003) 247-254
210. Liberatore G.T., Wong J.Y., Porritt M.J., Donnan G.A., and Howells D.W. Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. Neuroreport 8 (1997) 3097-3101
211. Liberto C.M., Albrecht P.J., Herx L.M., Yong V.W., and Levison S.W. Pro-regenerative properties of cytokine-activated astrocytes. J. Neurochem. 89 (2004) 1092-1100
212. Lim E. A walk through the management of Parkinson's disease. Ann. Acad. Med. Singapore 34 (2005) 188-195
213. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
214. Lin L.F., Zhang T.J., Collins F., and Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63 (1994) 758-768
215. Liu J., Albers M.W., Wandless T.J., Luan S., Alberg D.G., Belshaw P.J., Cohen P., MacKintosh C., Klee C.B., and Schreiber S.L. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31 (1992) 3896-3901
216. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., and Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39 (1996) 89-94
217. Logroscino G., Sesso H.D., Paffenbarger Jr. R.S., and Lee I.M. Physical activity and risk of Parkinson's disease: a prospective cohort study. J. Neurol. Neurosurg. Psychiatry 77 (2006) 1318-1322
218. Lopez-Martin E., Caruncho H.J., Rodriguez-Pallares J., Guerra M.J., and Labandeira-Garcia J.L. Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. J. Comp. Neurol. 406 (1999) 199-206
219. Lopez-Ramirez M.A., Dominguez-Monzon G., Vergara P., and Segovia J. Gas1 reduces Ret tyrosine 1062 phosphorylation and alters GDNF-mediated intracellular signaling. Int. J. Dev. Neurosci. 26 (2008) 497-503
220. Mabandla M., Kellaway L., St. Clair G.A., and Russell V.A. Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab. Brain Dis. 19 (2004) 43-50
221. Mandel S., Grunblatt E., Maor G., and Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 27 (2002) 1231-1243
222. Mandel S., Weinreb O., Amit T., and Youdim M.B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48 (2005) 379-387
223. Manson A.J., Hanagasi H., Turner K., Patsalos P.N., Carey P., Ratnaraj N., and Lees A.J. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 124 (2001) 331-340
224. Marco S., Canudas A.M., Canals J.M., Gavalda N., Perez-Navarro E., and Alberch J. Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp. Neurol. 174 (2002) 243-252
225. Martin B., Mattson M.P., and Maudsley S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev. 5 (2006) 332-353
226. Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Yodim M., Furukawa S., Nabeshima T., and Naoi M. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem. Int. 44 (2004) 393-400
227. Masana M.I., and Dubocovich M.L. Melatonin receptor signaling: finding the path through the dark. Sci. STKE 2001 (2001) E39
228. Maswood N., Young J., Tilmont E., Zhang Z., Gash D.M., Gerhardt G.A., Grondin R., Roth G.S., Mattison J., Lane M.A., Carson R.E., Cohen R.M., Mouton P.R., Quigley C., Mattson M.P., and Ingram D.K. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 18171-18176
229. Matsushita N., Fujita Y., Tanaka M., Nagatsu T., and Kiuchi K. Cloning and structural organization of the gene encoding the mouse glial cell line-derived neurotrophic factor, GDNF. Gene 203 (1997) 149-157
230. Mattson M.P. Energy intake, meal frequency, and health: a neurobiological perspective. Annu. Rev. Nutr. 25 (2005) 237-260
231. Mattson M.P., and Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7 (2006) 278-294
232. Mattson M.P., Duan W., Wan R., and Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 1 (2004) 111-116
233. McNaught K.S., and Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neurosci. Lett. 285 (2000) 61-65
234. Mellstrom B., Cena V., Lamas M., Perales C., Gonzalez C., and Naranjo J.R. Gas1 is induced during and participates in excitotoxic neuronal death. Mol. Cell. Neurosci. 19 (2002) 417-429
235. Mena M.A., Davila V., and Sulzer D. Neurotrophic effects of l-DOPA in postnatal midbrain dopamine neuron/cortical astrocytes cocultures. J. Neurochem. 69 (1997) 1398-1408
236. Mercier G., Lennon A.M., Renouf B., Dessouroux A., Ramauge M., Courtin F., and Pierre M. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J. Mol. Neurosci. 24 (2004) 207-216
237. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12 (1993) 2005-2015
238. Milanini J., Vinals F., Pouyssegur J., and Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273 (1998) 18165-18172
239. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., Lampe P.A., Heuckeroth R.O., Kotzbauer P.T., Simburger K.S., Golden J.P., Davies J.A., Vejsada R., Kato A.C., Hynes M., Sherman D., Nishimura M., Wang L.C., Vandlen R., Moffat B., Klein R.D., Poulsen K., Gray C., Garces A., and Johnson Jr. E.M. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 (1998) 245-253
240. Miskolci V., Castro-Alcaraz S., Nguyen P., Vancura A., Davidson D., and Vancurova I. Okadaic acid induces sustained activation of NFkappaB and degradation of the nuclear IkappaBalpha in human neutrophils. Arch. Biochem. Biophys. 417 (2003) 44-52
241. Mitchell I.J., Hughes N., Carroll C.B., and Brotchie J.M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol. 6 (1995) 492-507
242. Miyajima H., Osanai M., Chiba H., Nishikiori N., Kojima T., Ohtsuka K., and Sawada N. Glyceraldehyde-derived advanced glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes. Biochem. Biophys. Res. Commun. 330 (2005) 361-366
243. Miyazaki H., Nagashima K., Okuma Y., and Nomura Y. Expression of glial cell line-derived neurotrophic factor induced by transient forebrain ischemia in rats. Brain Res. 922 (2001) 165-172
244. Miyazaki H., Okuma Y., Nomura J., Nagashima K., and Nomura Y. Age-related alterations in the expression of glial cell line-derived neurotrophic factor in the senescence-accelerated mouse brain. J. Pharmacol. Sci. 92 (2003) 28-34
245. Mizoule J., Meldrum B., Mazadier M., Croucher M., Ollat C., Uzan A., Legrand J.J., Gueremy C., and Le F.G. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 24 (1985) 767-773
246. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., and Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 310 (2001) 117-120
247. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 279 (2000) 751-755
248. Mogi M., Harada M., Kondo T., Riederer P., and Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J. Neural Transm. 103 (1996) 1077-1081
249. Mogi M., Togari A., Kondo T., Mizuno Y., Kogure O., Kuno S., Ichinose H., and Nagatsu T. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci. Lett. 300 (2001) 179-181
250. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., and Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 270 (1999) 45-48
251. Moore K.W., de Waal M.R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
252. Moore M.W., Klein R.D., Farinas I., Sauer H., Armanini M., et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382 (1996) 76-79
253. Morale M.C., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., and Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138 (2006) 869-878
254. Moretto G., Walker D.G., Lanteri P., Taioli F., Zaffagnini S., Xu R.Y., and Rizzuto N. Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes in vitro. Cell Tissue Res. 286 (1996) 257-262
255. Moynagh P.N., Williams D.C., and O'Neill L.A. Interleukin-1 activates transcription factor NF kappa B in glial cells. Biochem. J. 294 Pt 2 (1993) 343-347
256. Murphy K.J., Fox G.B., Foley A.G., Gallagher H.C., O'Connell A., Griffin A., Nau H., and Regan C.M. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J. Neurochem. 78 (2001) 704-714
257. Murray H.E., Pillai A.V., McArthur S.R., Razvi N., Datla K.P., Dexter D.T., and Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116 (2003) 213-222
258. Mytilineou C., and Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45 (1985) 1951-1953
259. Nakagawa T., and Schwartz J.P. Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol. 14 (2004) 275-280
260. Nakagawa T., Yabe T., and Schwartz J.P. Gene expression profiles of reactive astrocytes cultured from dopamine-depleted striatum. Neurobiol. Dis. 20 (2005) 275-282
261. Nakajima K., Hida H., Shimano Y., Fujimoto I., Hashitani T., Kumazaki M., Sakurai T., and Nishino H. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res. 916 (2001) 76-84
262. Nakashima S., Matsuyama Y., Yu Y., Katayama Y., Ito Z., and Ishiguro N. Expression of GDNF in spinal cord injury and its repression by ONO-1714. Neuroreport 16 (2005) 17-20
263. Nakashima S., Matsuyama Y., Yu Y., Kiuchi K., and Ishiguro N. Suppression of GDNF production by MPSS treatment following spinal cord injury in the rat. Neuroreport 15 (2004) 2337-2340
264. Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., and Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 339 (2006) 915-922
265. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., and Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165 (2000) 136-142
266. Nash J.E., Hill M.P., and Brotchie J.M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. 155 (1999) 42-48
267. Naskar R., Vorwerk C.K., and Dreyer E.B. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1940-1944
268. Naughton C.K., Jain S., Strickland A.M., Gupta A., and Milbrandt J. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol. Reprod. 74 (2006) 314-321
269. 3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7 (1996) 2171-2175
270. Neeper S.A., Gomez-Pinilla F., Choi J., and Cotman C. Exercise and brain neurotrophins. Nature 373 (1995) 109
271. Nichols M., Weih F., Schmid W., DeVack C., Kowenz-Leutz E., Luckow B., Boshart M., and Schutz G. Phosphorylation of CREB affects its binding to high and low affinity sites: implications for cAMP induced gene transcription. EMBO J. 11 (1992) 3337-3346
272. Nicole O., Ali C., Docagne F., Plawinski L., MacKenzie E.T., Vivien D., and Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J. Neurosci. 21 (2001) 3024-3033
273. Niles L.P., Armstrong K.J., Rincon Castro L.M., Dao C.V., Sharma R., McMillan C.R., Doering L.C., and Kirkham D.L. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci. 5 (2004) 41
274. Nishiguchi M., Tokugawa K., Yamamoto K., Akama T., Nozawa Y., Chaki S., Ueki T., Kameo K., and Okuyama S. Increase in secretion of glial cell line-derived neurotrophic factor from glial cell lines by inhibitors of vacuolar ATPase. Neurochem. Int. 42 (2003) 493-498
275. Nishinakamura R., Matsumoto Y., Nakao K., Nakamura K., Sato A., Copeland N.G., Gilbert D.J., Jenkins N.A., Scully S., Lacey D.L., Katsuki M., Asashima M., and Yokota T. Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development 128 (2001) 3105-3115
276. Nitta A., Nishioka H., Fukumitsu H., Furukawa Y., Sugiura H., Shen L., and Furukawa S. Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. J. Neurosci. Res. 78 (2004) 250-258
277. Niwa M., Nitta A., Yamada K., and Nabeshima T. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J. Pharmacol. Sci. 104 (2007) 116-121
278. Nosheny R.L., Bachis A., Acquas E., and Mocchetti I. Human immunodeficiency virus type 1 glycoprotein gp120 reduces the levels of brain-derived neurotrophic factor in vivo: potential implication for neuronal cell death. Eur. J. Neurosci. 20 (2004) 2857-2864
279. Nosheny R.L., Bachis A., Aden S.A., De Bernardi M.A., and Mocchetti I. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J. Neurobiol. 66 (2006) 1311-1321
280. Nosrat C.A., Tomac A., Hoffer B.J., and Olson L. Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. Exp. Brain Res. 115 (1997) 410-422
281. O'Dell S.J., Gross N.B., Fricks A.N., Casiano B.D., Nguyen T.B., and Marshall J.F. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience 144 (2007) 1141-1151
282. Oh-Hashi K., Kaneyama M., Hirata Y., and Kiuchi K. ER calcium discharge stimulates GDNF gene expression through MAPK-dependent and -independent pathways in rat C6 glioblastoma cells. Neurosci. Lett. 405 (2006) 100-105
283. Ohta K., Fujinami A., Kuno S., Sakakimoto A., Matsui H., Kawahara Y., and Ohta M. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71 (2004) 162-168
284. Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H., and Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci. 73 (2003) 617-626
285. Ohta K., Ohta M., Mizuta I., Fujinami A., Shimazu S., Sato N., Yoneda F., Hayashi K., and Kuno S. The novel catecholaminergic and serotoninergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. Neurosci. Lett. 328 (2002) 205-208
286. Ohta M., Mizuta I., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272 (2000) 18-22
287. Ohto H., Kamada S., Tago K., Tominaga S.I., Ozaki H., Sato S., and Kawakami K. Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya. Mol. Cell. Biol. 19 (1999) 6815-6824
288. Okun E., Saida H., Albeck M., Sredni B., and Avtalion R.R. Upregulation of carp GDNF mRNA by the immunomodulator AS101. Dev. Comp. Immunol. 30 (2006) 441-446
289. Olanow C.W., Agid Y., Mizuno Y., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19 (2004) 997-1005
290. Olson A.K., Eadie B.D., Ernst C., and Christie B.R. Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways. Hippocampus 16 (2006) 250-260
291. 2-induced neuronal death. Neurobiol. Dis. 20 (2005) 141-154
292. Oo T.F., Kholodilov N., and Burke R.E. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J. Neurosci. 23 (2003) 5141-5148
293. Oo T.F., Ries V., Cho J., Kholodilov N., and Burke R.E. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat. J. Comp. Neurol. 484 (2005) 57-67
294. Otto D., and Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10 (1990) 1912-1921
295. Otto D., and Unsicker K. FGF-2 modulates dopamine and dopamine-related striatal transmitter systems in the intact and MPTP-lesioned mouse. Eur. J. Neurosci. 5 (1993) 927-932
296. Page G., Peeters M., Maloteaux J.M., and Hermans E. Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine. Eur. J. Pharmacol. 403 (2000) 75-80
297. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., and Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10 (1999) 557-561
298. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol. 59 (2002) 1937-1943
299. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
300. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61 (2004) 561-566
301. Parkinson F.E., Sinclair C.J., Othman T., Haughey N.J., and Geiger J.D. Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. Neuropharmacology 43 (2002) 836-846
302. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
303. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., and Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. (2008) doi:10.1038/nn.2136
304. Peeters M., Page G., Maloteaux J.M., and Hermans E. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res. 949 (2002) 32-41
305. Peng C., Fan S., Li X., Fan X., Ming M., Sun Z., and Le W. Overexpression of pitx3 upregulates expression of BDNF and GDNF in SH-SY5Y cells and primary ventral mesencephalic cultures. FEBS Lett. 581 (2007) 1357-1361
306. Peng G.S., Li G., Tzeng N.S., Chen P.S., Chuang D.M., Hsu Y.D., Yang S., and Hong J.S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134 (2005) 162-169
307. Perrelet D., Ferri A., Liston P., Muzzin P., Korneluk R.G., and Kato A.C. IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo. Nat. Cell Biol. 4 (2002) 175-179
308. Pertusa M., Garcia-Matas S., Mammeri H., Adell A., Rodrigo T., Mallet J., Cristofol R., Sarkis C., and Sanfeliu C. Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol. Aging 29 (2008) 1366-1379
309. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
310. Peterson A.L., and Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5 (2008) 270-280
311. Pezeshki G., Franke B., and Engele J. Evidence for a ligand-specific signaling through GFRalpha-1, but not GFRalpha-2, in the absence of Ret. J. Neurosci. Res. 66 (2001) 390-395
312. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
313. Pichel J.G., Shen L., Sheng H.Z., Granholm A.C., Drago J., et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382 (1996) 73-76
314. Platania P., Seminara G., Aronica E., Troost D., Vincenza C.M., and Angela S.M. 17beta-Estradiol rescues spinal motoneurons from AMPA-induced toxicity: a role for glial cells. Neurobiol. Dis. 20 (2005) 461-470
315. Pochon N.A., Menoud A., Tseng J.L., Zurn A.D., and Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur. J. Neurosci. 9 (1997) 463-471
316. Pong K., and Zaleska M.M. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr. Drug. Targets CNS Neurol. Disord. 2 (2003) 349-356
317. Poteryaev D., Titievsky A., Sun Y.F., Thomas-Crusells J., Lindahl M., Billaud M., Arumae U., and Saarma M. GDNF triggers a novel Ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1. FEBS Lett. 463 (1999) 63-66
318. Pothos E.N., Davila V., and Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J. Neurosci. 18 (1998) 4106-4118
319. Presgraves S.P., Borwege S., Millan M.J., and Joyce J.N. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp. Neurol. 190 (2004) 157-170
320. Przuntek H., Conrad B., Dichgans J., Kraus P.H., Krauseneck P., Pergande G., Rinne U., Schimrigk K., Schnitker J., and Vogel H.P. SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur. J. Neurol. 6 (1999) 141-150
321. Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., Inzelberg R., Djaldetti R., Klein C., and Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23 (2000) 324-330
322. Ramirez A.D., Liu X., and Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77 (2003) 223-231
323. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 (2000) 1484-1491
324. Reeben M., Laurikainen A., Hiltunen J.O., Castren E., and Saarma M. The messenger RNAs for both glial cell line-derived neurotrophic factor receptors, c-ret and GDNFRalpha, are induced in the rat brain in response to kainate-induced excitation. Neuroscience 83 (1998) 151-159
325. Reiter R.J., Tan D.X., and Pappolla M.A. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann. NY Acad. Sci. 1035 (2004) 179-196
326. Remy S., Naveilhan P., Brachet P., and Neveu I. Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J. Neurosci. Res. 64 (2001) 242-251
327. Remy S., Naveilhan P., Paille V., Brachet P., and Neveu I. Lipopolysaccharide and TNFalpha regulate the expression of GDNF, neurturin and their receptors. Neuroreport 14 (2003) 1529-1534
328. Righi M., Tongiorgi E., and Cattaneo A. Brain-derived neurotrophic factor (BDNF) induces dendritic targeting of BDNF and tyrosine kinase B mRNAs in hippocampal neurons through a phosphatidylinositol-3 kinase-dependent pathway. J. Neurosci. 20 (2000) 3165-3174
329. Rodriguez C., Mayo J.C., Sainz R.M., Antolin I., Herrera F., Martin V., and Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36 (2004) 1-9
330. Ron D., and Janak P.H. GDNF and addiction. Rev. Neurosci. 16 (2005) 277-285
331. Ross D.T., Guo H., Howorth P., Chen Y., Hamilton G.S., and Steiner J.P. The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats. Neurosci. Lett. 297 (2001) 113-116
332. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., and Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23 (2003) 349-357
333. Saavedra A., Baltazar G., and Duarte E.P. Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. Neurobiol. Dis. 25 (2007) 92-104
334. Saavedra A., Baltazar G., Carvalho C.M., and Duarte E.P. GDNF modulates HO-1 expression in substantia nigra postnatal cell cultures. Free Radic. Biol. Med. 39 (2005) 1611-1619
335. Saavedra A., Baltazar G., Santos P., Carvalho C.M., and Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 23 (2006) 533-542
336. Sagi Y., Mandel S., Amit T., and Youdim M.B. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25 (2007) 35-44
337. Sajadi A., Bensadoun J.C., Schneider B.L., Lo B.C., and Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol. Dis. 22 (2006) 119-129
338. Sajithlal G., Zou D., Silvius D., and Xu P.X. Eya1 acts as a critical regulator for specifying the metanephric mesenchyme. Dev. Biol. 284 (2005) 323-336
339. Salvatore M.F., Zhang J.L., Large D.M., Wilson P.E., Gash C.R., Thomas T.C., Haycock J.W., Bing G., Stanford J.A., Gash D.M., and Gerhardt G.A. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J. Neurochem. 90 (2004) 245-254
340. Sanchez B., Lopez-Martin E., Segura C., Labandeira-Garcia J.L., and Perez-Fernandez R. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res. Mol. Brain Res. 108 (2002) 143-146
341. Sanchez M.P., Silos-Santiago I., Frisen J., He B., Lira S.A., et al. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382 (1996) 70-73
342. Sariola H., and Saarma M. Novel functions and signalling pathways for GDNF. J. Cell Sci. 116 (2003) 3855-3862
343. Satake K., Matsuyama Y., Kamiya M., Kawakami H., Iwata H., Adachi K., and Kiuchi K. Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury. Neuroreport 11 (2000) 3877-3881
344. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., and Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44 (1998) 110-119
345. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., and Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J. Neurosci. Res. 54 (1998) 707-719
346. Sawada H., Ibi M., Kihara T., Urushitani M., Nakanishi M., Akaike A., and Shimohama S. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J. Neurochem. 74 (2000) 1175-1184
347. Schaar D.G., Sieber B.A., Dreyfus C.F., and Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol. 124 (1993) 368-371
348. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
349. Schinelli S. Pharmacology and physiopathology of the brain endothelin system: an overview. Curr. Med. Chem. 13 (2006) 627-638
350. Schlee S., Carmillo P., and Whitty A. Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nat. Chem. Biol. 2 (2006) 636-644
351. Schmidt-Kastner R., Tomac A., Hoffer B., Bektesh S., Rosenzweig B., and Olson L. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarine-induced status epilepticus in rats. Brain Res. Mol. Brain Res. 26 (1994) 325-330
352. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251 (1991) 283-287
353. Schueler-Furman O., Glick E., Segovia J., and Linial M. Is GAS1 a co-receptor for the GDNF family of ligands?. Trends Pharmacol. Sci. 27 (2006) 72-77
354. Shao Z., Dyck L.E., Wang H., and Li X.M. Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J. Psychiatry Neurosci. 31 (2006) 32-37
355. Sharma R., McMillan C.R., Tenn C.C., and Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068 (2006) 230-236
356. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21 (2006) 136-141
357. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., Knoll J., and Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. Eur. J. Pharmacol. 421 (2001) 181-189
358. Shimazu S., Tanigawa A., Sato N., Yoneda F., Hayashi K., and Knoll J. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci. 72 (2003) 2785-2792
359. Shimazu S., Tsunekawa H., Yoneda F., Katsuki H., Akaike A., and Janowsky A. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. Eur. J. Pharmacol. 482 (2003) 9-16
360. Shults C.W., Ray J., Tsuboi K., and Gage F.H. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res. 883 (2000) 192-204
361. Siderowf A., and Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology 66 (2006) S80-S88
362. Siegel G.J., and Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 33 (2000) 199-227
363. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
364. Smidt M.P., Smits S.M., and Burbach J.P. Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra. Cell Tissue Res. 318 (2004) 35-43
365. Smith A.D., and Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol. 184 (2003) 31-39
366. Smith A.D., Antion M., Zigmond M.J., and Austin M.C. Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat. Brain Res. Mol. Brain Res. 117 (2003) 129-138
367. Smith M.P., and Cass W.A. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci. Lett. 412 (2007) 259-263
368. Soderstrom K., O'Malley J., Steece-Collier K., and Kordower J.H. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 15 (2006) 251-265
369. Sontag E., Sontag J.M., and Garcia A. Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation. EMBO J. 16 (1997) 5662-5671
370. Sosa I., Reyes O., and Kuffler D.P. Immunosuppressants: neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions. Exp. Neurol. 195 (2005) 7-15
371. Springer J.E., Mu X., Bergmann L.W., and Trojanowski J.Q. Expression of GDNF mRNA in rat and human nervous tissue. Exp. Neurol. 127 (1994) 167-170
372. Sredni B., Caspi R.R., Klein A., Kalechman Y., Danziger Y., Ben Y.M., Tamari T., Shalit F., and Albeck M. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 330 (1987) 173-176
373. Sredni B., Geffen-Aricha R., Duan W., Albeck M., Shalit F., Lander H.M., Kinor N., Sagi O., Albeck A., Yosef S., Brodsky M., Sredni-Kenigsbuch D., Sonino T., Longo D.L., Mattson M.P., and Yadid G. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. Faseb J. 21 (2007) 1870-1883
374. Steiner B., Winter C., Hosman K., Siebert E., Kempermann G., Petrus D.S., and Kupsch A. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 199 (2006) 291-300
375. Steiner J.P., Dawson T.M., Fotuhi M., Glatt C.E., Snowman A.M., Cohen N., and Snyder S.H. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358 (1992) 584-587
376. Steiner J.P., Hamilton G.S., Ross D.T., Valentine H.L., Guo H., Connolly M.A., Liang S., Ramsey C., Li J.H., Huang W., Howorth P., Soni R., Fuller M., Sauer H., Nowotnik A.C., and Suzdak P.D. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2019-2024
377. Storch A., Burkhardt K., Ludolph A.C., and Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75 (2000) 2259-2269
378. Strassmann G., Kambayashi T., Jacob C.O., and Sredni D. The immunomodulator AS-101 inhibits IL-10 release and augments TNF alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. Cell. Immunol. 176 (1997) 180-185
379. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., and Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 124 (1993) 401-412
380. Subramony J.A. Apomorphine in dopaminergic therapy. Mol. Pharm. 3 (2006) 380-385
381. Suter-Crazzolara C., and Unsicker K. GDNF is expressed in two forms in many tissues outside the CNS. Neuroreport 5 (1994) 2486-2488
382. Suter-Crazzolara C., and Unsicker K. GDNF mRNA levels are induced by FGF-2 in rat C6 glioblastoma cells. Brain Res. Mol. Brain. Res. 41 (1996) 175-182
383. Sutoo D., and Akiyama K. Regulation of brain function by exercise. Neurobiol. Dis. 13 (2003) 1-14
384. Takahashi H., Funahashi H., Sawai H., Sakamoto M., Matsuo Y., Yamamoto M., Okada Y., Hayakawa T., and Manabe T. Glial cell line-derived neurotrophic factor enhances nuclear factor-kappaB activity and invasive potential in human pancreatic cancer cells. Pancreas 29 (2004) 22-27
385. Takahata K., Shimazu S., Katsuki H., Yoneda F., and Akaike A. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural Transm. 113 (2006) 151-158
386. Takayama H., Ray J., Raymon H.K., Baird A., Hogg J., Fisher L.J., and Gage F.H. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat. Med. 1 (1995) 53-58
387. Tan Y., Low K.G., Boccia C., Grossman J., and Comb M.J. Fibroblast growth factor and cyclic AMP (cAMP) synergistically activate gene expression at a cAMP response element. Mol. Cell. Biol. 14 (1994) 7546-7556
388. Tan Y., Rouse J., Zhang A., Cariati S., Cohen P., and Comb M.J. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 15 (1996) 4629-4642
389. Tanaka K., Asanuma M., and Ogawa N. Molecular basis of anti-apoptotic effect of immunophilin ligands on hydrogen peroxide-induced apoptosis in human glioma cells. Neurochem. Res. 29 (2004) 1529-1536
390. Tanaka K., Fujita N., and Ogawa N. Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain. Brain Res. 970 (2003) 250-253
391. Tanaka K., Fujita N., Higashi Y., and Ogawa N. Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. Neurosci. Lett. 330 (2002) 147-150
392. Tanaka K., Yoshioka M., Miyazaki I., Fujita N., and Ogawa N. GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. Neurosci. Lett. 321 (2002) 45-48
393. Tanaka M., Ito S., and Kiuchi K. Novel alternative promoters of mouse glial cell line-derived neurotrophic factor gene. Biochim. Biophys. Acta 1494 (2000) 63-74
394. Tanaka T., Oh-Hashi K., Shitara H., Hirata Y., and Kiuchi K. NF-kappaB independent signaling pathway is responsible for LPS-induced GDNF gene expression in primary rat glial cultures. Neurosci. Lett. 431 (2008) 262-267
395. Tang Y.P., Ma Y.L., Chao C.C., Chen K.Y., and Lee E.H. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. 53 (1998) 593-604
396. Tatton W.G., and Greenwood C.E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30 (1991) 666-672
397. Tatton W.G., Wadia J.S., Ju W.Y., Chalmers-Redman R.M., and Tatton N.A. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Transm. Suppl. 48 (1996) 45-59
398. Thiffault C., Aumont N., Quirion R., and Poirier J. Effect of MPTP and l-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65 (1995) 2725-2733
399. Thomas B., and Mohanakumar K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J. Pineal Res. 36 (2004) 25-32
400. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119 (2003) 899-911
401. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21 (2001) 4427-4435
402. Tokugawa K., Yamamoto K., Nishiguchi M., Sekine T., Sakai M., Ueki T., Chaki S., and Okuyama S. XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1. Neurochem. Int. 42 (2003) 81-86
403. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., and Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8274-8278
404. Tooyama I., Kawamata T., Walker D., Yamada T., Hanai K., Kimura H., Iwane M., Igarashi K., McGeer E.G., and McGeer P.L. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43 (1993) 372-376
405. Toyomoto M., Inoue S., Ohta K., Kuno S., Ohta M., Hayashi K., and Ikeda K. Production of NGF, BDNF and GDNF in mouse astrocyte cultures is strongly enhanced by a cerebral vasodilator, ifenprodil. Neurosci. Lett. 379 (2005) 185-189
406. Treanor, J.J., Goodman, L., de, S.F., Stone, D.M., Poulsen, K.T., Beck, C.D., Gray, C., Armanini, M.P., Pollock, R.A., Hefti, F., Phillips, H.S., Goddard, A., Moore, M.W., Buj-Bello, A., Davies, A.M., Asai, N., Takahashi, M., Vandlen, R., Henderson, C.E., Rosenthal, A., 1996. Characterization of a multicomponent receptor for GDNF. Nature 382, 80-83.
407. Trupp M., Arenas E., Fainzilber M., Nilsson A.S., Sieber B.A., Grigoriou M., Kilkenny C., Salazar-Grueso E., Pachnis V., and Arumae U. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 (1996) 785-789
408. Trupp M., Belluardo N., Funakoshi H., and Ibanez C.F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 17 (1997) 3554-3567
409. Trupp M., Ryden M., Jornvall H., Funakoshi H., Timmusk T., Arenas E., and Ibanez C.F. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J. Cell Biol. 130 (1995) 137-148
410. Trupp M., Scott R., Whittemore S.R., and Ibanez C.F. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J. Biol. Chem. 274 (1999) 20885-20894
411. Tsai C.H., Lo S.K., See L.C., Chen H.Z., Chen R.S., Weng Y.H., Chang F.C., and Lu C.S. Environmental risk factors of young onset Parkinson's disease: a case-control study. Clin. Neurol. Neurosurg. 104 (2002) 328-333
412. Tsuchioka M., Takebayashi M., Hisaoka K., Maeda N., and Nakata Y. Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells. J. Neurochem. 106 (2008) 244-257
413. Vega-Naredo I., Poeggeler B., Sierra-Sanchez V., Caballero B., Tomas-Zapico C., Varez-Garcia O., Tolivia D., Rodriguez-Colunga M.J., and Coto-Montes A. Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture. J. Pineal Res. 39 (2005) 266-275
414. Verity A.N., Wyatt T.L., Hajos B., Eglen R.M., Baecker P.A., and Johnson R.M. Regulation of glial cell line-derived neurotrophic factor release from rat C6 glioblastoma cells. J. Neurochem. 70 (1998) 531-539
415. Verity A.N., Wyatt T.L., Lee W., Hajos B., Baecker P.A., Eglen R.M., and Johnson R.M. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J. Neurosci. Res. 55 (1999) 187-197
416. + in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. Faseb J. (2008) doi: 10.1096/fj.07-095398
417. Vitkovic L., Maeda S., and Sternberg E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 9 (2001) 295-312
418. Wang C.Y., Yang F., He X., Chow A., Du J., Russell J.T., and Lu B. Ca(2+) binding protein frequenin mediates GDNF-induced potentiation of Ca(2+) channels and transmitter release. Neuron 32 (2001) 99-112
419. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., and Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 904 (2001) 67-75
420. 2+ channels and excitatory synaptic transmission in midbrain dopaminergic neurons. Neurosignals 12 (2003) 78-88
421. Wang X.J., Chen X.H., Yang X.Y., Geng M.Y., and Wang L.M. Acidic oligosaccharide sugar chain, a marine-derived oligosaccharide, activates human glial cell line-derived neurotrophic factor signaling. Neurosci. Lett. 417 (2007) 176-180
422. Wang Y., Chang C.F., Morales M., Chiang Y.H., and Hoffer J. Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann. NY Acad. Sci. 962 (2002) 423-437
423. Wang Y., Chiang Y.H., Su T.P., Hayashi T., Morales M., Hoffer B.J., and Lin S.Z. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 39 (2000) 873-880
424. Wei G., Wu G., and Cao X. Dynamic expression of glial cell line-derived neurotrophic factor after cerebral ischemia. Neuroreport 11 (2000) 1177-1183
425. Wellik D.M., Hawkes P.J., and Capecchi M.R. Hox11 paralogous genes are essential for metanephric kidney induction. Genes Dev. 16 (2002) 1423-1432
426. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., and Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003) 93-101
427. Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr. Drug Targets 2 (2001) 285-298
428. Witt-Enderby P.A., MacKenzie R.S., McKeon R.M., Carroll E.A., Bordt S.L., and Melan M.A. Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor. Cell Motil. Cytoskel. 46 (2000) 28-42
429. Woodbury D., Schaar D.G., Ramakrishnan L., and Black I.B. Novel structure of the human GDNF gene. Brain Res. 803 (1998) 95-104
430. Wu S.S., and Frucht S.J. Treatment of Parkinson's disease: what's on the horizon?. CNS Drugs 19 (2005) 723-743
431. Xia C.F., Boado R.J., Zhang Y., Chu C., and Pardridge W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med. 10 (2008) 306-315
432. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-kappaB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269 (1994) 4705-4708
433. Xiong H., Futamura T., Jourdi H., Zhou H., Takei N., Verse-Pierluissi M., Plevy S., and Nawa H. Neurotrophins induce BDNF expression through the glutamate receptor pathway in neocortical neurons. Neuropharmacology 42 (2002) 903-912
434. Xu P.X., Adams J., Peters H., Brown M.C., Heaney S., and Maas R. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat. Genet. 23 (1999) 113-117
435. Yamagata K., Hakata K., Maeda A., Mochizuki C., Matsufuji H., Chino M., and Yamori Y. Adenosine induces expression of glial cell line-derived neurotrophic factor (GDNF) in primary rat astrocytes. Neurosci. Res. 59 (2007) 467-474
436. Yamagata K., Tagami M., Ikeda K., Tsumagari S., Yamori Y., and Nara Y. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) mRNA expression during hypoxia and reoxygenation in astrocytes isolated from stroke-prone spontaneously hypertensive rats. Glia 37 (2002) 1-7
437. Yamashita M., Dimayuga P., Kaul S., Shah P.K., Regnstrom J., Nilsson J., and Cercek B. Phosphatase activity in the arterial wall after balloon injury: effect of somatostatin analog octreotide. Lab. Invest. 79 (1999) 935-944
438. Yang F., Feng L., Zheng F., Johnson S.W., Du J., Shen L., Wu C.P., and Lu B. GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat. Neurosci. 4 (2001) 1071-1078
439. Yang L.X., and Nelson P.G. Glia cell line-derived neurotrophic factor regulates the distribution of acetylcholine receptors in mouse primary skeletal muscle cells. Neuroscience 128 (2004) 497-509
440. Yoon M.C., Shin M.S., Kim T.S., Kim B.K., Ko I.G., Sung Y.H., Kim S.E., Lee H.H., Kim Y.P., and Kim C.J. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats. Neurosci. Lett. 423 (2007) 12-17
441. Yoshida T., Tanaka M., Suzuki Y., Sohmiya M., and Okamoto K. Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats. Neurosci. Lett. 330 (2002) 1-4
442. Yoshioka M., Tanaka K., Miyazaki I., Fujita N., Higashi Y., Asanuma M., and Ogawa N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res. 43 (2002) 259-267
443. Youdim M.B., Maruyama W., and Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc.) 41 (2005) 369-391
444. Young D., Lawlor P.A., Leone P., Dragunow M., and During M.J. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat. Med. 5 (1999) 448-453
445. Yu H., Oh-Hashi K., Tanaka T., Sai A., Inoue M., Hirata Y., and Kiuchi K. Rehmannia glutinosa induces glial cell line-derived neurotrophic factor gene expression in astroglial cells via cPKC and ERK1/2 pathways independently. Pharmacol. Res. 54 (2006) 39-45
446. Yu Y., Matsuyama Y., Yanase M., Ito S., Adachi K., Satake K., Ishiguro N., and Kiuchi K. Effects of hyperbaric oxygen on GDNF expression and apoptosis in spinal cord injury. Neuroreport 15 (2004) 2369-2373
447. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276 (2001) 31674-31683
448. Yurek D.M., and Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res. 891 (2001) 228-235
449. Yurek D.M., and Fletcher-Turner A. Temporal changes in the neurotrophic environment of the denervated striatum as determined by the survival and outgrowth of grafted fetal dopamine neurons. Brain Res. 931 (2002) 126-134
450. Zhang C., Steiner J.P., Hamilton G.S., Hicks T.P., and Poulter M.O. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J. Neurosci. 21 (2001) RC156
451. Zhang W.R., Hayashi T., Iwai M., Nagano I., Sato K., Manabe Y., and Abe K. Time dependent amelioration against ischemic brain damage by glial cell line-derived neurotrophic factor after transient middle cerebral artery occlusion in rat. Brain Res. 903 (2001) 253-256
452. +. FEBS Lett. 582 (2008) 956-960
453. Zhou J., Yu Y., Tang Z., Shen Y., and Xu L. Differential expression of mRNAs of GDNF family in the striatum following 6-OHDA-induced lesion. Neuroreport 11 (2000) 3289-3293